Drug Trial Radar · NCT07708441
A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
914
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension. To explore the optimal use of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension。
Conditions
- Uncontrolled or Resistant Hypertension
Interventions
HRS-1780 tabletDrug
HRS-1780 tablet Dose 1
HRS-1780 tabletDrug
HRS-1780 tablet Dose 2
HRS-1780 tabletDrug
HRS-1780 tablet Dose 3
HRS-1780 tablet placeboDrug
HRS-1780 tablet placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in trough seated SBP at Week 12Time frame: baseline and Week 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Army Characteristic Medical Center of the People's Liberation Army
Chongqing, Chongqing Municipality, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.